



Regeneron Announces Presentation at the ISI Annual Conference

February 8, 2011

TARRYTOWN, N.Y., Feb. 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the ISI Annual Conference on Tuesday, February 15, 2011. The presentation is scheduled for 2:10 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through March 17, 2011.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Contact Information:

Michael Aberman, M.D.	Peter Dworkin
Investor Relations	Corporate Communications
914.345.7799	914.345.7800
michael.aberman@regeneron.com	peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media